Aptevo Therapeutics Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey G. Lamothe
- Full Time Employees
- 37
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2401 4th Avenue Seattle WA United States of America 98121
- IPO Date
- Jul 20, 2016
- CIK
- 0001671584
- Website
- aptevotherapeutics.com
- Similar Companies
- Business
- Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company headquartered in Seattle, Washington and founded in 2016 as a spin-off from Emergent BioSolutions Inc., focuses on developing novel bispecific and trispecific immunotherapies for cancer treatment using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. The company advances a pipeline including two clinical-stage candidates—mipletamig (CD123 x CD3 bispecific T-cell engager in Phase 1b/2 for frontline acute myeloid leukemia, demonstrating 89% remission rates in evaluable frontline patients across two trials with no cytokine release syndrome observed) and ALG.APV-527 (5T4 x 4-1BB bispecific conditional agonist co-developed with Alligator Bioscience in Phase 1 for solid tumors including non-small cell lung cancer, head and neck, colorectal, pancreatic and breast cancers)—along with six preclinical candidates such as APVO603, APVO442 and APVO711 targeting solid tumors including prostate cancer. These multispecific antibody candidates enhance immune system activation against hematologic malignancies and solid tumors primarily in the United States. In recent developments, Aptevo introduced its first trispecific T-cell engagers APVO451 (for multiple solid tumors) and APVO452 (for prostate cancer) in 2025, expanding its CD3-directed portfolio to five molecules leveraging the CRIS-7-derived CD3 binding domain for improved safety; the company raised approximately $22.8 million in equity financing since Q2 2025 through at-the-market offerings and a Standby Equity Purchase Agreement, extending its cash runway into Q4 2026.
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D.
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why
Aptevo Provides State of the Business Report and 2025 Financial Results
Aptevo to Participate in March 2026 Conferences
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Decline in Short Interest
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Drop in Short Interest
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Drops By 86.5%
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
What's Going On With Aptevo Therapeutics Stock Today?
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Critical Contrast: Aptevo Therapeutics (NASDAQ:APVO) vs. Neumora Therapeutics (NASDAQ:NMRA)
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors